FDA Approves New Type 2 Diabetes Drug Bexagliflozin FDA Approves New Type 2 Diabetes Drug Bexagliflozin
Another SGLT2 inhibitor has been approved for type 2 diabetes based on results from 23 clinical trials that included 5000 patients and more than 300 patients who also had stage 3 chronic kidney disease.Medscape Medical News
Source: Medscape Diabetes Headlines - Category: Endocrinology Tags: Diabetes & Endocrinology News Alert Source Type: news
More News: Chronic Kidney Disease | Clinical Trials | Diabetes | Diabetes Type 2 | Endocrinology | SGLT2 Inhibitors | Urology & Nephrology